Thirty-one House members, most of whom, public records show, got campaign dollars from compound drug lobbyists, are pressing the Defense Department to soften rules set in May that block TRICARE coverage of compound medicines when medical efficacy is unproven or prices extreme. Defense officials say they don't intend to relax the rules created to protect TRICARE from aggressive marketing and abusive pricing that have polluted the compound drug industry. Indeed, TRICARE has had to tweak the new rules five times since May 1 just to close more loopholes that industry seemed ready to exploit, possibly sending TRICARE drug costs soaring again. For more details, see this Military Advantage blog post.